Home ›
T-Cell Lymphoma Lymphoma Trials ›
NCT07074457
Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
To evaluate the efficacy and safety of chidamide combined with brentuximab vedotin regimen for CD30 positive PTCL patients who are unfit for chemotherapy.
Trial Details
NCT ID NCT07074457
Phase NA
Sponsor The First Affiliated Hospital of Soochow University
Status RECRUITING
Cancer Type T-Cell Lymphoma Lymphoma
Interventions Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide) Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide) Maintenance therapy-chidamide
Locations (sample) Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
Age ≥70 years or age \< 70 years and unfit for chemotherapy, male or female not limited; Patients must have the capacity to understand and willingly provide written informed consent; ECOG score 0-3 points; Expected lifespan\>3 months;
For full eligibility, visit ClinicalTrials.gov .